ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Beyond the visual T2-FLAIR mismatch: quantitative imaging markers of IDH mutation in Gliomas-A retrospective diagnostic accuracy study.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate noninvasive prediction of isocitrate dehydrogenase (IDH) mutation status is essential for the classification, prognostication, and management of diffuse gliomas. PURPOSE: To evaluate quantitative and semi-quantitative T2-FLAIR-based MRI parameters for differentiating IDH-mutant from IDH-wildtype gliomas.
methodsThis retrospective study included 29 patients with histopathologically confirmed diffuse gliomas who underwent preoperative 1.5-T brain MRI. Quantitative parameters (rT2, rFLAIR, and mismatch [rT2-rFLAIR]) were calculated using region-of-interest measurements relative to contralateral normal parenchyma. A semi-quantitative T2-FLAIR mismatch score (1-4) was assessed on subtraction images. Groups were compared using the Mann-Whitney U test. Diagnostic performance was evaluated using ROC analysis, including comparison of correlated AUCs. Univariable and exploratory adjusted logistic regression analyses were performed, and interobserver agreement for the mismatch score was assessed.
resultsNineteen tumors were IDH-wildtype and ten were IDH-mutant. IDH-mutant gliomas showed significantly higher rFLAIR and rT2 values (p = 0.016 and p < 0.001, respectively). The mismatch score was significantly higher in IDH-mutant tumors (median [IQR]: 3 [3-4] vs. 1 [1-2], p < 0.001). ROC analysis demonstrated excellent performance for the mismatch score (AUC = 0.95) and rT2 (AUC = 0.94). A mismatch score ≥ 3 yielded 90% sensitivity and 89.5% specificity. Both the mismatch score and rT2 showed the strongest associations with IDH mutation status. Interobserver agreement was substantial (weighted κ = 0.67; 95% CI: 0.43-0.83). The AUCs of the mismatch score and rT2 did not differ significantly (p = 0.861). Quantitative mismatch was higher in IDH-mutant tumors but did not reach statistical significance (p = 0.070). In exploratory models adjusted for age and lesion size, rT2 and mismatch score remained significantly associated with IDH-mutant status.
conclusionQuantitative and semi-quantitative T2-FLAIR-based parameters showed promising performance for differentiating IDH-mutant from IDH-wildtype gliomas in this cohort. However, because 1p/19q co-deletion status was unavailable, these findings require validation in cohorts with complete molecular classification.
Indexed as
Identifiers
42726300What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.